NCT06057922 2026-03-12
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Active not recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Ascentage Pharma Group Inc.
Shanghai Institute Of Biological Products
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Suzhou Suncadia Biopharmaceuticals Co., Ltd.